Novo Nordisk Secures FDA Approval for 7.2mg Wegovy HD; U.S. Distribution Begins April
The FDA approved a 7.2mg dose of Wegovy HD for long-term weight management, granting Novo Nordisk a priority review voucher. STEP-UP Phase 3 data showed patients lost an average of 20.7% body weight over 72 weeks, and U.S. distribution begins in April, although shares fell roughly 2% on the announcement.
1. FDA Approval Details
The U.S. Food and Drug Administration granted approval for a higher 7.2mg dosage of Wegovy HD, enhancing Novo Nordisk’s obesity treatment lineup. The approval included a Commissioner's National Priority Review Voucher, which could expedite future key public health product reviews.
2. Clinical Trial Results
Data from the STEP-UP Phase 3 program demonstrated an average weight loss of 20.7% over 72 weeks for patients on the 7.2mg dose of semaglutide. These results reinforce the therapy’s efficacy in supporting sustained weight reduction.
3. Commercial Rollout and Market Impact
Novo Nordisk plans to begin U.S. distribution of the single-dose Wegovy HD pen in April. Despite the positive regulatory and clinical milestones, the company’s shares declined about 2% on the day of the announcement, reflecting investor caution amid competitive GLP-1 market dynamics.